Starlab and Neuroelectrics Join PREDICTOM to Improve Early Detection of Alzheimer’s Disease
Starlab and Neuroelectrics have officially joined the PREDICTOM project. This EU-funded initiative is working to develop an AI-based tool that can detect signs of Alzheimer’s disease earlier than today’s methods. With dementia cases expected to double in the EU by 2050, early detection is more important than ever for patients, families, and healthcare systems.
Giulio Ruffini, CTO and Co-Founder of Neuroelectrics
Two Companies, One Shared Goal
Starlab will contribute its expertise in brain signal analysis to the project. The company works with technologies like brain stimulation, brain activity measurements (EEG), and artificial intelligence (AI) to better understand how the brain works and changes.
– We will bring our methodological portfolio of different approaches to analyze the EEG data collected at PREDICTOM. It includes connectivity, complexity, and other techniques that we would like to employ for the AI-based early detection of cognitive decline, says Aureli Soria-Frisch, Director of Neuroscience at Starlab.
Neuroelectrics brings experience with wireless EEG devices and computational brain modeling. Their goal is to make it easier to monitor brain health both in clinics and at home using safe, easy-to-use technology.
– We aim to bring brain monitoring closer to people, whether they are in a clinic or at home. Our wireless EEG systems can make early detection of Alzheimer’s simpler and more scalable, says Giulio Ruffini, CTO and Co-Founder of Neuroelectrics.
Tools for Better Data Collection
Neuroelectrics will provide five advanced wireless EEG systems to several clinical sites within the project. These devices offer high-quality, easy-to-collect brain data, essential for identifying early neurological changes indicative of Alzheimer’s.
– These tools enable comprehensive brain health assessments, critical for early and personalized interventions, says Francesca Castaldo, Senior Researcher at Neuroelectrics.
Francesca Castaldo, Senior Researcher at Neuroelectrics
From Brain Signals to Better Insights
Starlab’s role is to help identify biomarkers—measurable signals in the brain that indicate early changes linked to Alzheimer’s. They will use machine learning to analyze EEG signals and improve how we detect, track, and treat the disease.
– EEG is a cost-effective and easy-to-use technology to monitor the electrical activity in the brain. Transcranial electrical stimulation (tES) is its counterpart, a technology whereby brain activity is modulated through the application of low-intensity electrical currents. It is being investigated as a neuroprotective intervention to delay Alzheimer’s disease, explains Soria-Frisch.
Neuroelectrics also emphasizes the potential of combining EEG data with other medical data such as MRI, blood samples, and eye-tracking to improve prediction accuracy.
New Ways to Understand the Brain
The company will use advanced brain modeling to create “neurotwins,” virtual models of each person’s brain. These models can help researchers understand how the disease progresses and explore possible treatments in a safe, simulated environment.
– Our neurotwins integrate EEG data with complementary biomarkers, such as MRI and eye-tracking, to greatly enhance predictive accuracy. This approach helps researchers and clinicians tailor interventions specifically to each patient,” says Giulio Ruffini.
Wireless EEG also enables larger population studies. It can make brain monitoring more affordable, flexible, and accessible in the future.
Moving Brain Science Forward
Starlab sees great value in contributing to PREDICTOM.
– The access to PREDICTOM data and to the first-line expert group in the consortium will allow us to achieve a breakthrough in our digital biomarkers for the diagnosis of Alzheimer’s disease or for patient stratification in AD clinical trials, says Soria-Frisch.
EEG-based tools could help detect cognitive decline much earlier and at a lower cost than traditional methods.
– This can potentially change how the entire sector operates, leading to a range of new products and services, and clearly improving clinical practice, he adds.
A Shared Mission to Help People Sooner
By joining PREDICTOM, both Starlab and Neuroelectrics bring valuable tools and know-how to a project that could help millions. Together, they aim to make early detection of Alzheimer’s faster, simpler, and more tailored to each person.
Aureli Soria-Frisch, Director of Neuroscience at Starlab
Moving Brain Science Forward
Starlab sees great value in contributing to PREDICTOM.
– The access to PREDICTOM data and to the first-line expert group in the consortium will allow us to achieve a breakthrough in our digital biomarkers for the diagnosis of Alzheimer’s disease or for patient stratification in AD clinical trials, says Soria-Frisch.
EEG-based tools could help detect cognitive decline much earlier and at a lower cost than traditional methods.
– This can potentially change how the entire sector operates, leading to a range of new products and services, and clearly improving clinical practice, he adds.
A Shared Mission to Help People Sooner
By joining PREDICTOM, both Starlab and Neuroelectrics bring valuable tools and know-how to a project that could help millions. Together, they aim to make early detection of Alzheimer’s faster, simpler, and more tailored to each person.
